drugset / Trial / NCT03589040

Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant

NCT03589040

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the pharmacokinetic properties of rilpivirine and darunavir when used in combination with etonogestrel

Timeline

Start
2018-09-25
Primary completion
2019-06
Completion
2020-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg Oral
Subject Etonogestrel Unknown 68 mg Other
Subject Rilpivirine Small molecule 25 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral